Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Edgewise Therapeutics, Inc. (EWTX) had Consolidated Net Income/Loss of $-133.81M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-133.81M |
|
-- |
|
-- |
|
$158.83M |
|
$-158.83M |
|
$25.02M |
|
$-133.81M |
|
$-133.81M |
|
$-133.81M |
|
$-133.81M |
|
|
Consolidated Net Income/Loss |
$-133.81M |
$-133.81M |
|
$-158.83M |
|
$-169.09M |
|
92.42M |
|
92.42M |
|
$-1.45 |
|
$-1.45 |
|
| Balance Sheet Financials | |
$475.48M |
|
$9.50M |
|
$11.33M |
|
$486.82M |
|
$23.86M |
|
-- |
|
$3.74M |
|
$27.60M |
|
$459.22M |
|
$459.22M |
|
$459.22M |
|
94.84M |
|
| Cash Flow Statement Financials | |
$-109.03M |
|
$-184.66M |
|
$249.25M |
|
$86.10M |
|
$41.67M |
|
$-44.43M |
|
$24.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-110.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-29.14% |
|
-29.14% |
|
-27.49% |
|
-29.14% |
|
$4.84 |
|
$-1.19 |
|
$-1.18 |
|